Medicinova (MNOV) Receives Nortice of Allowance from EPO for MN-029 Patent

January 14, 2016 7:33 AM EST

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

MediciNova, Inc.,(Nasdaq: MNOV) announced receipt from the European Patent Office of a notice of intent to allow patent for MN-029 (denibulin) di-hydrochloride.

Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than July 2032. The allowed claims cover the compound, pharmaceutical compositions and a method of treating certain cell proliferative diseases, including cancer, using MN-029 (denibulin) di-hydrochloride. MediciNova intends to use MN-029 (denibulin) di-hydrochloride in future development.

"We are very pleased that the European Patent Office will grant our compound patent for MN-029 as we believe it could substantially increase the potential value of MN-029. We will now consider developing a program for MN-029 in Europe," commented Yuichi Iwaki, MD, PhD, President and CEO of MediciNova, Inc.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, Litigation, Management Comments